Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia
NCT03992313 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7692
Last updated 2025-06-22
Summary
Objectives Principal objective: to compare the effectiveness of a community-based intervention to a facility-based intervention to improve the combined-testing uptake (Antibody + RNA) of HCV infection among general population aged more than 40 years old in Cambodia Secondary objectives
* To compare the HCV antibody testing uptake between the 2 arms for the eligible population
* To compare the active case detection rate between the 2 arms for the eligible population
* To compare the linkage to care between the 2 arms for those with active infection
* To compare the cost-effectiveness of the two strategies
* To evaluate the treatment uptake
* To evaluate the effectiveness and safety of a 12-week dual-therapy of direct-acting antiviral (DAA) treatment
Conditions
- Hepatitis C
- Testing
Interventions
- OTHER
-
Community-based HCV rapid test
HCV rapid tests will be done in the village
- OTHER
-
Facility-based HCV rapid test
HCV rapid tests will be done in the health center
- OTHER
-
Plasmatic HCV viral load
HCV viral load will be done in provincial hospital on plasma using GenXpert
- OTHER
-
DBS HCV viral load
HCV viral load will be done in Phnom Penh by DBS using Omunis kit
Sponsors & Collaborators
-
University of Health Sciences, Phnom Penh, Cambodia
collaborator UNKNOWN -
Hopital Paul Brousse
collaborator OTHER -
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV -
Fondation Mérieux
collaborator OTHER -
University of Marseille
collaborator OTHER -
SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD)
collaborator UNKNOWN -
ANRS, Emerging Infectious Diseases
lead OTHER_GOV
Principal Investigators
-
Vonthanak Saphonn, PhD · Saglik Bilimleri Universitesi
-
Jean-Charles Duclos-Vallee, PhD · Paul Brousse hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-04-21
- Primary Completion
- 2023-09-23
- Completion
- 2023-09-23
Countries
- Cambodia
Study Locations
More Related Trials
-
The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset
NCT05713136 ·Status: RECRUITING
-
Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)
NCT03939013 ·Status: COMPLETED ·Phase: NA
-
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
NCT04405024 ·Status: SUSPENDED ·Phase: NA
-
Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China(STAT)
NCT05906459 ·Status: UNKNOWN
-
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
NCT03244371 ·Status: UNKNOWN ·Phase: NA
-
HCV Self-testing in Malaysia
NCT04982718 ·Status: UNKNOWN ·Phase: NA
-
Early Detection of HCV in Injection Drug Users
NCT06431945 ·Status: RECRUITING
-
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
NCT00308048 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care
NCT02084719 ·Status: TERMINATED ·Phase: NA
-
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
NCT00709228 ·Status: COMPLETED
-
The DETECT HCV Screening Trial
NCT04003454 ·Status: COMPLETED ·Phase: NA
-
Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar
NCT03579576 ·Status: COMPLETED
-
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
NCT04971330 ·Status: COMPLETED
-
Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders
NCT01725542 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
NCT05506475 ·Status: NOT_YET_RECRUITING
-
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
NCT01667081 ·Status: COMPLETED
-
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
NCT02170727 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
NCT02333292 ·Status: COMPLETED
-
Screening for Hepatitis C Using a Rapid Diagnostic Orientation Test (TROD) in Patients Over 50 Years Old in the Digestive Endoscopy Department of the Europeen Hospital Marseille
NCT05103085 ·Status: UNKNOWN
-
The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
NCT05248555 ·Status: RECRUITING
-
Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia
NCT02628691 ·Status: TERMINATED
-
Antiviral Activity of AZD7295 in HCV Carriers
NCT00781976 ·Status: COMPLETED ·Phase: PHASE1
-
A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
NCT03099135 ·Status: TERMINATED ·Phase: PHASE3
-
12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
NCT00069511 ·Status: UNKNOWN ·Phase: PHASE2
-
Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
NCT01054742 ·Status: COMPLETED